Omnicell/$OMCL
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Omnicell
Omnicell Inc provides automation and business analytics software for healthcare providers. The company is engaged in transforming the pharmacy and nursing care delivery model. The company helps its customers define and deliver cost-effective medication management designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks and drive improved clinical, operational, and financial outcomes across all care settings. The company derives the majority of its revenue from the United States.
Ticker
$OMCL
Sector
Primary listing
Employees
3,670
Headquarters
Website
Omnicell Metrics
BasicAdvanced
$1.6B
84.01
$0.43
0.88
-
Price and volume
Market cap
$1.6B
Beta
0.88
52-week high
$51.85
52-week low
$22.66
Average daily volume
378K
Financial strength
Current ratio
1.445
Quick ratio
0.933
Long term debt to equity
15.963
Total debt to equity
15.963
Interest coverage (TTM)
2.73%
Profitability
EBITDA (TTM)
68.55
Gross margin (TTM)
43.44%
Net profit margin (TTM)
1.69%
Operating margin (TTM)
1.23%
Effective tax rate (TTM)
41.80%
Revenue per employee (TTM)
$320,000
Management effectiveness
Return on assets (TTM)
0.43%
Return on equity (TTM)
1.62%
Valuation
Price to earnings (TTM)
84.011
Price to revenue (TTM)
1.405
Price to book
1.33
Price to tangible book (TTM)
5.23
Price to free cash flow (TTM)
17.656
Free cash flow yield (TTM)
5.66%
Free cash flow per share (TTM)
2.024
Growth
Revenue change (TTM)
10.67%
Earnings per share change (TTM)
-210.18%
3-year revenue growth (CAGR)
-3.47%
10-year revenue growth (CAGR)
9.49%
3-year earnings per share growth (CAGR)
-25.04%
10-year earnings per share growth (CAGR)
-7.01%
What the Analysts think about Omnicell
Analyst ratings (Buy, Hold, Sell) for Omnicell stock.
Bulls say / Bears say
Following temporary U.S. tariff relief on Chinese imports, Omnicell raised the lower end of its 2025 adjusted EPS guidance to $1.30 (from $1.00), signaling management’s confidence in margin recovery as cost pressures ease (Reuters)
In Q3 2025, Omnicell reported revenue of $310.6 million (up 10% y/y) and adjusted EPS of $0.51, beating analyst estimates and prompting management to raise full-year revenue guidance to $1.177–1.187 billion (Associated Press)
Omnicell aims for a 14%–15% CAGR to reach $1.9–$2.0 billion in revenue by 2025, driven by growth in technology services, long-term sole-source partnerships, and bigger deal sizes (Nasdaq)
The reinstatement of higher tariffs after the temporary reduction is projected to pose a $40 million EBITDA headwind in 2025, as each 25% tariff reduction below 145% results in only about $2 million in savings (Reuters)
Omnicell’s GAAP net income dropped to $5 million in Q3 2025 from $9 million a year ago, showing continued margin pressure despite revenue growth (BioSpace)
Bank of America lowered its price target, citing limited visibility into near-term product revenue growth, highlighting uncertainty in Omnicell’s core automation hardware segment (Nasdaq)
Data summarised monthly by Lightyear AI. Last updated on 3 Nov 2025.
Omnicell Financial Performance
Revenues and expenses
Omnicell Earnings Performance
Company profitability
Omnicell News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Omnicell stock?
Omnicell (OMCL) has a market cap of $1.6B as of November 07, 2025.
What is the P/E ratio for Omnicell stock?
The price to earnings (P/E) ratio for Omnicell (OMCL) stock is 84.01 as of November 07, 2025.
Does Omnicell stock pay dividends?
No, Omnicell (OMCL) stock does not pay dividends to its shareholders as of November 07, 2025.
When is the next Omnicell dividend payment date?
Omnicell (OMCL) stock does not pay dividends to its shareholders.
What is the beta indicator for Omnicell?
Omnicell (OMCL) has a beta rating of 0.88. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.